IMA: Immuno-Magnetic Assay

All assays developed at BluSense are based on the Immuno-magnetic assay (IMA) patented opto-magnetic readout technique. IMA is a novel methodology to quantitatively measure the presence of biomarkers (antigens and/or antibodies) into a biological matrix based on aggregation of magnetic nanoparticles.

Year IMA patented


Agreement with ELISA


Sample-to-answer time

∼10 min

How does IMA work?

When running a test, blood flows into micro-fluidic channels, where plasma is separated from red blood cells by centrifugation. Plasma is then transferred into the reaction and readout chambers, where it dissolves the reagents, blocking buffer and dry magnetic nanoparticles. Magnetic nanoparticles, coated with a specific antigen or antibody, trap the target analyte. A magnetic field is then repeatedly applied to align the nanoparticles into chains and to increase the chains in size and in number.
Finally, a blue laser light is shone through the sample while an oscillating magnetic field is applied. In a negative sample, single particles do not produce a measurable signal.  In a positive sample, nanoparticle chains rotate, scattering the light and producing a signal. The more the analyte, the more the nanoclusters, the higher the signal.

Integrated micro-centrifugation

Automated plasma separation

Nanoparticles mix with sample

Homogeneous format, no washing needed

Nanoparticles bind to analyte

Magnetic enhanced reaction

Magnetic rotation and detection

Rapid and quantitative patented IMA readout


BluSense Diagnostics
Fruebjergvej 3
DK-2100 København Ø
+45 39 17 97 14

Sign up for our newsletter
You have been successfully Subscribed! Ops! Something went wrong, please try again.